XML 45 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Mar. 24, 2023
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Period End Date Dec. 31, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus FY  
Trading Symbol ACRV  
Entity Registrant Name Acrivon Therapeutics, Inc.  
Entity Central Index Key 0001781174  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Common Stock, Shares Outstanding   21,920,634
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity File Number 001-41551  
Entity Tax Identification Number 82-5125532  
Entity Address, Address Line One 480 Arsenal Way  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Watertown  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02472  
City Area Code 617  
Local Phone Number 207-8979  
Entity Incorporation, State or Country Code DE  
Entity Interactive Data Current Yes  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Security Exchange Name NASDAQ  
Document Annual Report true  
Document Transition Report false  
ICFR Auditor Attestation Flag false  
Documents Incorporated by Reference

Portions of the Registrant's definitive Proxy Statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III.

  
Auditor Firm ID 238  
Auditor Name PricewaterhouseCoopers LLP  
Auditor Location Boston, Massachusetts, United States  
Entity Public Float $ 0